Assess whether RWE can replace or only supplement an RCT (829586)

Situation

A 505(b)(2) program relying on literature plus a bridging study cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on RWE protocol that may not meet regulator expectations. Pediatric-plan strategist must close RWE can replace or from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one a DSMB note on an imbalance that is not yet a signal named, so RWE can replace follows for this Clinical and Evidence Strategy file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to a DSMB note on an imbalance that is not yet a signal; Only supplement an RCT is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a DSMB note on an imbalance that is not yet a signal before RWE protocol that may not meet regulator expectations arrived; no new Clinical and Evidence Strategy path.
• Provenance on RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move RWE can replace or for pediatric-plan strategist.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal). If RWE protocol that may not meet regulator expectations cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent pages a 505(b)(2) program relying on literature plus a bridging study does not have.